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Neglect in the numbers: 
leaving no voice behind 
in disease elimination
For any disease nearing elimination, 
adding precision to data is a must. 
In The Lancet Global Health, the 
Local Burden of Disease (LBD) 
2019 Neglected Tropical Diseases 
(NTD) Collaborators have presented 
geospatial estimates of the global 
prevalence of lymphatic filariasis at a 
welcome level of precision, with the 
aim to identify areas where additional 
programme investment (data and 
treatment) might be needed to reach 
elimination goals.1 We think a clear 
direction for investment should be 
in rethinking  disease management, 
disability, and inclusion (DMDI).
Although progress towards 
eliminating lymphatic filariasis 
continues, the DMDI components 
of elimination programmes are 
often neglected, a point rightfully 
highlighted in the Comment by Joseph 
Kamgno and Hugues Nana Djeunga.2 
The new NTD roadmap and the 
elimination dossier both emphasise 
providing a minimum package of care 
for patients with lymphoedema and 
hydrocele as crucial to the validation of 
elimination targets. In our experience, 
this DMDI minimum package is not 
only rarely implemented, but also 
insufficient in its scope. The current 
medical management of these 
conditions fails to address chronic 
stressors associated with lymphatic 
filariasis, such as stigma, isolation, and 
economic hardship,3 and omits mental 
health as an important component of 
care. The narrow and vertical focus4 of 
the minimum package can also limit 
its ability to meet peoples’ needs, and 
fails to capitalise on opportunities 
for strengthening lymphatic filariasis 
management by collaboration with 
other disease programmes, mental 
health services, and disability and 
inclusion programmes.
The Global Programme to Eliminate 
Lymphatic Filariasis was formed in 
response to lymphatic filariasis being 
the second leading cause of permanent 
and long-term disability.2 Clearly, the 
needs and priorities of people affected 
by lymphatic filariasis—estimated to 
be more than 35 million—should be 
at the centre of health service design 
and delivery.5 A reliance on siloed and 
verticalised approaches to the provision 
of care is likely to limit progress towards 
universal health coverage and impede 
the attainment of good health and 
wellbeing for affected people. Papers, 
such as the one by the LBD 2019 NTD 
Collaborators,1 which focus on infection 
prevalence as the sole measure of 
elimination, omit the mention of 
DMDI, and refer to the stopping 
of programmes upon elimination, 
unwillingly contribute to the invisibility 
of those with life-altering morbidity as 
a result of lymphatic filariasis.
We advocate for an increased focus 
on implementation research that 
seeks to understand and address 
health system barriers to ensuring a 
holistic continuum of care for people 
with lymphatic filariasis. Approaches 
that put people and communities 
at the centre, recognising them as 
assets in the coproduction of health 
and social care, are essential in 
driving this agenda forward. Data 
drawn from patient experiences 
should be given the same weight as 
projections of disease distribution in 
decision making regarding disease 
elimination. This rethinking is crucial 
for lymphatic filariasis, but also 
extends to other diseases that are 
being added to the NTD portfolio. We 
must avoid making the same mistakes 
in neglecting to adequately consider 
the provision of holistic support for 
affected individuals, particularly those 
for whom mass drug administration 
campaigns might come too late.
A focus on people and not diseases, 
and country-owned systems that 
reflect the values, needs, and 
experiences of people affected 
by NTDs, their households, and 
communities, are vitally important to 
ensure that DMDI strategies are truly 
person-centred and address avoidable, 
unfair, and unjust health outcomes for 
the most vulnerable.
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